Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials-Reference-Cited by-同舟云学术

Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials

Published:2022-04 Issue:2 Volume:7 Page:100433
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Guarneri V.,Griguolo G.,Miglietta F.,Conte P.F.,Dieci M.V.,Girardi F.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference25 articles.

1. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis;Cortazar;Lancet,2014

2. Trastuzumab containing regimens for early breast cancer;Moja;Cochrane Database Syst Rev,2012

3. Trastuzumab-containing regimens for metastatic breast cancer;Balduzzi;Cochrane Database Syst Rev,2014

4. Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives;Guarneri;Cancer Lett,2007

5. Eighth Edition of the AJCC cancer staging manual: breast cancer;Giuliano;Breast Oncol,2018

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study);BMC Cancer;2024-01-17

2. Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now;Breast Cancer Research;2023-10-03

3. Risk-Based Therapeutic Strategies for HER2-Positive Early Breast Cancer: A Consensus Paper;Clinical Breast Cancer;2023-10

4. Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer;npj Breast Cancer;2023-09-27

5. Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review;Cancers;2023-08-30